OneSource Specialty Pharma Q1 FY27: Earnings Call July 25

Earnings call on July 25: what the company has announced

OneSource Specialty Pharma Ltd will hold an earnings call on Saturday, July 25, 2026, at 10:00 AM IST. The company said the call will discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). For investors, the update is a key checkpoint after a volatile FY26 that included a sharp Q4 rebound and management reiterations around FY27 momentum.

The announcement also lands amid active sell-side preview work, with some estimates pegging Q1 FY27 revenue in a narrow band and profit expectations still conservative. Alongside the scheduled call, the broader context includes FY28 guidance statements (in US dollars) and commentary around proposed acquisitions that could lift medium-term revenue potential.

Q1 FY27 expectations: the preview framework in the market

A Q1 FY27 preview in the provided information uses a trailing-growth framework applied to a Q1 FY26 base of INR 3,330 million revenue and INR 0 million net profit. Based on the most recent year-on-year growth signal referenced from Q4 FY26, the estimate range for Q1 FY27 revenue is INR 3,100 to 3,570 million.

The same preview set a profit estimate of INR 0 to 0 million for the quarter. It also listed an indicative results window of July to August 2026 for the quarter’s financial disclosure cadence.

Separately, the stock’s context in the preview note included a current market price (CMP) of Rs. 1,702, and a 12-month target range of Rs. 1,623 to Rs. 1,844.

Unaudited Q1 performance figures cited alongside the call

Alongside the call announcement, the provided text includes a set of Q1 financial performance numbers attributed to OneSource Specialty Pharma Limited. These figures show revenue of INR 3,273 million, up 12% year-on-year, and EBITDA of INR 885 million, up 37% year-on-year.

The same information set reports adjusted PAT of INR 371 million, described as positive versus a loss in the previous year. It also states that the EBITDA margin improved by 500 basis points to 27%, and that adjusted EPS was INR 3.20 per share on a fully diluted basis.

In addition, another data point describes revenue at ₹327.27 crore (equivalent to INR 3,272.7 million), presented as a 23.17% QoQ decrease from ₹425.95 crore (equivalent to INR 4,259.5 million), and a 317.49% YoY increase. Operating profit is cited at ₹32.75 crore (equivalent to INR 327.5 million), down 9.78% QoQ from ₹36.30 crore (equivalent to INR 363.0 million), and up 51.55% YoY.

Q4 FY26 recap: rebound quarter and what drove it

OneSource’s Q4 FY26 numbers in the text point to a significant sequential recovery. Management commentary states Q4 revenues were INR 4,282 million, representing 47% sequential growth, supported by performance across service offerings and the India Semaglutide commercial launch toward the end of the quarter.

On profitability, Q4 FY26 EBITDA is cited at INR 919 million, described as more than 5x sequentially, with margin expansion of 1,550 basis points quarter-on-quarter, linked to operating leverage on higher CSA revenues. Adjusted PAT for the quarter is given as INR 390 million, compared with a loss in the previous quarter, implying a loss-to-profit shift within FY26.

A separate line in the supplied material also references Q4 revenue at “almost US$18 million”, up “almost 47% from the previous quarter,” aligning directionally with the INR-based sequential recovery narrative.

Full-year FY26: revenue decline and the stated reason

For FY26, the company reported INR 14,216 million in revenue, described as a 2% decline year-on-year. The explanation given in management commentary points to a softer prior quarter driven by delayed Semaglutide approvals in Canada.

FY26 adjusted PAT is cited at INR 739 million. The same commentary adds that FY26 EBITDA declined about 35% due to delayed Semaglutide approvals that weighed on the second half of results.

Long-term guidance: US$100 million organic target, plus a US$100 million ambition with M&A

Management statements included in the text reaffirm a long-term guidance target of FY28 organic revenue of US$100 million with an EBITDA margin of around 40%. The same narrative indicates confidence in a strong FY27 and reiterates the FY28 guidance.

In parallel, another line in the provided information states that management aims to touch USD 500 million revenue (including the proposed acquisition of injectable assets) with an EBITDA margin of around 40% by FY28. This framing suggests two reference points: an organic FY28 guidance and a broader ambition including inorganic contribution.

The text also notes that proposed acquisitions, if completed, could add combined revenue potential of $100 million by FY27, with EBITDA in the range of 36% to 40%.

Key numbers snapshot (all revenues normalised to INR million)

Q1 FY27 estimate range versus base quarter (INR million)

Market impact: what investors may track around the call

The earnings call timing matters because it follows a Q4 FY26 rebound where revenue reached INR 4,282 million and EBITDA reached INR 919 million. Investors typically use such calls to test whether a sharp sequential recovery is sustaining into the next quarter, especially when management links performance to approvals, launches, and capacity build-out.

The call also comes with competing signposts in the public domain: a preview range of INR 3,100 to 3,570 million for Q1 FY27 revenue, and a separate set of Q1 figures showing INR 3,273 million revenue and INR 885 million EBITDA. With the stock referenced at Rs. 1,702 and a 12-month target band of Rs. 1,623 to Rs. 1,844, clarity on demand, execution, and margin trajectory can influence near-term positioning, even without making any forward price predictions.

Company details cited

The provided information includes the company’s registered office details as: 201 Devarata Sector 17 Vashi, Navi Mumbai Sanpada, Thane, Maharashtra-400703, Phone: 91-22-2789 2924/78929 08076.

What to watch next

The immediate next event is the July 25, 2026 earnings call to discuss unaudited Q1 FY27 results. Investors and analysts are likely to listen for confirmation of the quarter’s revenue and margin trajectory, updates on Semaglutide-related execution, and any additional detail on the company’s FY28 revenue and margin targets. Any further updates on proposed acquisitions and their potential contribution by FY27 would also be relevant, given the stated $100 million combined revenue potential cited in the supplied text.